2-FDCK

Buy 2-FDCK Online Europe

Buy 2-FDCK Online Europe ,2-FDCK powder for sale Germany , where to order 2-FDCK Powder in France , Purchase Research Chemical Austria

What is 2-FDCK?

2-FDCK, or 2-Fluorodeschloroketamine, is a dissociative anesthetic belonging to the arylcyclohexylamine class. It is structurally and pharmacologically similar to ketamine, a well-known anesthetic and analgesic, and deschloroketamine (DCK), a ketamine analog. 2-FDCK has garnered attention in recent years as a research chemical, particularly within the psychonaut and harm reduction communities.

Originally synthesized for scientific investigation, 2-FDCK has been explored for its anesthetic and psychoactive properties. However, it is not approved for medical use in humans and has limited formal research behind its effects, metabolism, and long-term safety.

Chemical Structure and Relationship to Ketamine

Chemically, 2-FDCK is a fluorinated derivative of deschloroketamine, which itself is a derivative of ketamine without the chlorine atom. In 2-FDCK, a fluorine atom replaces the chlorine typically present on the phenyl ring in ketamine. This small modification can significantly influence the compound’s pharmacokinetics (how it’s processed in the body) and pharmacodynamics (how it interacts with the brain).

• IUPAC Name: 2-(2-Fluorophenyl)-2-methylamino-cyclohexanone

• Molecular Formula: C13H16FNO

• Molar Mass: ~221.27 g/mol

Because of its similarity to ketamine, it is believed to act on NMDA (N-methyl-D-aspartate) receptors, contributing to its dissociative and anesthetic effects. However, the exact binding affinities and metabolic pathways of 2-FDCK have not been fully elucidated.

Pharmacology and Effects

Like other dissociatives, 2-FDCK primarily affects the glutamatergic system, acting as an NMDA receptor antagonist. By blocking these receptors, the brain’s usual excitatory signals are interrupted, producing characteristic dissociative effects. Users often describe altered perception of time and space, feelings of detachment from the body, and changes in sensory perception.

Commonly Reported Effects:

• Dissociation

• Visual and auditory distortions

• Analgesia (pain reduction)

• Euphoria or mood elevation

• Impaired motor coordination

• Dream-like states or “K-hole” experiences at higher doses

• Cognitive impairment and short-term memory loss

Onset and Duration:

• Onset: 10–30 minutes (oral), 5–15 minutes (intranasal)

• Peak: 1–2 hours

• Total Duration: 4–6 hours

• After-effects: Up to 24 hours (including fatigue or mental fog)

It’s important to note that these figures can vary significantly depending on the route of administration, dose, individual metabolism, and tolerance.